文献速递分子诊断临床微生物

ResistancePlus MG 多重定量 PCR 检测生殖支原体及大环内酯耐药的前瞻性评估

Prospective Evaluation of ResistancePlus MG, a New Multiplex Quantitative PCR Assay for Detection of Mycoplasma genitalium and Macrolide Resistance.
PubMed 文献 · J Clin Microbiol · 2017-04-05

本研究在 1,089 份连续尿液和肛门生殖道拭子样本中评估 ResistancePlus MG 多重 qPCR 检测生殖支原体及大环内酯耐药突变的临床性能。与实验室验证的 16S rRNA qPCR 和 23S rRNA 测序相比,生殖支原体检测敏感性 98.5%、特异性 100%,耐药突变检测敏感性 100.0%、特异性 96.2%。该检测可同时提供病原体和耐药信息,在大环内酯耐药上升背景下具有临床优势。

要点

  • ResistancePlus MG 检测生殖支原体敏感性 98.5%、特异性 100%。
  • 耐药突变检测敏感性 100.0%、特异性 96.2%。
  • 可同时报告病原体和大环内酯耐药,指导治疗。

核心结论

  • ResistancePlus MG 多重 qPCR 可准确同时检测生殖支原体和大环内酯耐药突变。

研究设计与样本

  • 前瞻性评估 1,089 份连续尿液和肛门生殖道拭子样本,来自有症状和无症状的男性和女性患者。

主要发现

  • 6.0% 样本生殖支原体阳性,其中 63.1% 携带大环内酯耐药相关突变。
  • 生殖支原体检测敏感性 98.5%、特异性 100%。
  • 大环内酯耐药突变检测敏感性 100.0%、特异性 96.2%。

关键数值与推荐

  • 以实验室验证的靶向 16S rRNA 基因 qPCR 和 Sanger 测序检测 23S rRNA 突变为参考方法。

临床怎么用

  • 临床可用于生殖支原体检测并同时获得大环内酯耐药结果,辅助治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mycoplasma genitalium is a significant pathogen for which first-line treatment is becoming less effective due to increased resistance to macrolides. As conventional culture and antimicrobial susceptibility testing is not feasible for routine detection of this pathogen, molecular markers such as detection of mutations in the 23S rRNA gene have been described to predict resistance. Recently, a novel multiplex quantitative PCR (qPCR) assay, ResistancePlus MG, has been described for the simultaneous detection of Mycoplasma genitalium and macrolide resistance. In the current study, the clinical performance of the assay was evaluated on 1,089 consecutive urine and anogenital swab samples in symptomatic and asymptomatic male and female patients. Overall, 6.0% were positive for M. genitalium, with 63.1% having macrolide resistance-associated mutations. Compared to the laboratory-validated qPCR method targeting the 16S rRNA gene and Sanger sequencing to determine 23S rRNA mutations, the sensitivity and specificity of M. genitalium detection were 98.5% and 100% and for detection of macrolide resistance mutations were 100.0% and 96.2%, respectively. This assay offers a considerable advantage in clinical settings for M. genitalium testing by making the results of macrolide resistance and mutation analyses simultaneously available, which is increasingly important with escalating macrolide resistance.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Tabrizi SN, Su J, Bradshaw CS, et al. Prospective Evaluation of ResistancePlus MG, a New Multiplex Quantitative PCR Assay for Detection of Mycoplasma genitalium and Macrolide Resistance. J Clin Microbiol. 2017. PMID: 28381611. doi:10.1128/JCM.02312-16

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。